| Topic: | Diabetes (DM) |
| Title: | Insulin Analogues. |
| Author: | Buse, J.B. |
| Source: | Current Opinion in Endocrinology and Diabetes. 8(2): 95-100. April 2001. |
| Availability: | Available from Rapid Science Publishers. 400 Market Street, Suite 700, Philadelphia, PA 19106. (215) 574-2266. Fax (215) 574-2292. |
| Abstract: | This article presents some of the well documented findings concerning insulin analogues. These agents have been developed to provide more physiologic insulin replacement after subcutaneous injection than human insulin. Lispro insulin, the first rapid-acting insulin, was approved in 1998 for the treatment of diabetes. Numerous clinical trials have demonstrated the efficacy of lispro in reducing postprandial glucose elevations. More recently insulin aspart, a similar analogue, has become available. The two are of significant advantage in many patients with diabetes and produce reductions in postprandial hyperglycemia as well as in hypoglycemia risk. A comparison of available pharmacokinetic data suggests that aspart may have a longer half life than lispro insulin. If true, theoretically, it could prove advantageous in certain clinical scenarios and problematic in others, but it would provide more options in attempting to achieve precise physiologic replacement of insulin. Insulin glargine is a long acting insulin analogue, first marketed in Europe in 2000. It provides a peakless profile of activity with 24 hour action. Glargine reduces nocturnal hypoglycemia with more consistent and greater control of fasting glucose than available intermediate acting insulins. The availability of insulin analogues designed to produce novel patterns of activity provides new options for the treatment of diabetes to normalize glycemia and minimize the risk of hypoglycemia. 1 figure. 17 references. (AA-M). |
| Format: | Journal Article |
| Language: | English. |
| Major Keywords: | Diabetes Mellitus. Type 1 Diabetes. Type 2 Diabetes. Insulin. Drug Therapy. Lispro Insulin. Pharmacology. Drug Effects. Product Safety. |
| Minor Keywords: | Gestational Diabetes. Beta Cells. Blood Glucose. Hyperglycemia. Hypoglycemia. Glycosylated Hemoglobin. Human Insulin. Ultralente Insulin. Clinical Research. |
| Publication Number: | DMJA09716 |
| Return to Search Results | |